Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

ients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and a GLP-1 analog with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.4 million people are chronically infected with HCV and approximately 25,000 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
(Date:10/30/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, November 6, 2014, and that the ... at 1:30 p.m. PST that afternoon. Management will provide ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Replacing both knees in one surgery, or simultaneous ... fewer prosthetic joint infections as well as other revision ... total knee replacements performed in two separate procedures. However, ... of adverse cardiovascular outcomes within 30 days, according to ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... of the first patients treated with Zimmer MotionLoc™ Screws ... Screw is Zimmer Trauma,s latest advancement in locking plate technology and ... NCB ® Polyaxial Locking Plate System.   The ...
Cached Medicine Technology:Two Knee Replacements May Be Better Than One 2Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation 2Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation 3
(Date:10/30/2014)... Graphics, coding, typography and search engine ... craft of web design and require thorough knowledge to ... solution to create a website can be as easy ... customer reviews and Facebook posts all accumulate on a ... next evolution of how a business can develop a ...
(Date:10/30/2014)... Austin, TX (PRWEB) October 30, 2014 ... is gifting PreD Store shoppers with a ... taken before meals to reduce post-meal blood sugar spikes. ... overall health is an important part of a diabetes ... on orders will receive one complimentary tube of sugardown. ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... South Carolina (PRWEB) October 30, 2014 ... and should be more vigorously exercised to help maintain ... recently authored the book ‘Dementia Express: Lose Your Memory ... book uses counterintuitive reasoning and sometimes conflicting attitudes to ... course for the mind, a reader must decipher the ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... as the incidence is likely to increase in the ... the course of Alzheimer's disease. There is a special ... messenger and this chemical//is regulated by a drug called ... enabled by the chemical glutamate. This happens when glutamate ...
... indicates lack of protein to development of cancer. Cells without ... either kill a cell or keep it from growing. However ... are able to multiply creating tumors. Researchers indicated that loss ... a normal cell the chance to change into a cancer ...
... In a recent study which examined the snoring habits ... them. People with chronic(15 headaches per month) daily headache ... chronic snorers than the people with occasional(104 headaches per ... and 65. When the researchers analysed people, those with ...
... indicates that Negative exercise electrocardiograph tests should ... of hypertensive patients with chest pain. Even ... risk, positive findings could not distinguish levels ... pharmacological stress echocardiography yielded diagnostic and prognostic ...
... first country to contain its SARS outbreak. Vietnam had five ... Hanoi's international hospital. There was about sixty three people affected ... there by reducing the rate of infection and keeping SARS ... have been reported from Vietnam since April 8.// The country ...
... in India went up to 10, authorities are not confident ... shown a far higher recovery rate than the rest of ... medical care provided to SARS patients. Even what we call ... are only between 60 and 65 per cent accurate according ...
Cached Medicine News:
BD Vacutainer® Fluoride Tubes - Glass...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: